[Automatically translated by Lingotek]
VitaDX International SA (Rennes) was founded in 2015 and aims to become a major player in early cancer diagnosis by leveraging image processing and Artificial Intelligence. In September, the company completed a financing round of 3 million euros with its historical investors: GO CAPITAL, ODYSSEE Venture and FFBB Management and its financial partners BNP Paribas, CIC Ouest, BPGO and Caisse d’Epargne.
In particular, this new funding will enable VitaDX t
o: Promote the solution to opinion leaders in urology and anatomopathology in Europe – Implement a
n ambitious strategy for access to reimbursement in Europe – Suppor
t the technical and regulatory advancement of VisioCyt® in th
e US – Continue the development of new indications exploiting VitaDX’s know-how and technological assets
“This funding positions VitaDX in an ideal position to meet the next challenge of commercializing visioCyt® and assert its leadership in the field of cancer diagnosis, image processing and artificial intelligence applied to pathology. »Allan RODRIGUEZ, Managing Director of VitaDX and Jacques Le Bozec, Chairman of VitaDX’s Board of Directors.
Publié le 26/10/2020